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Abstract
Fusion of the EWS gene to FLI1 produces a fusion oncoprotein that drives an aberrant gene expression program responsible
for the development of Ewing sarcoma. We used a homogenous proximity assay to screen for compounds that disrupt the
binding of EWS-FLI1 to its cognate DNA targets. A number of DNA-binding chemotherapeutic agents were found to non-
specifically disrupt protein binding to DNA. In contrast, actinomycin D was found to preferentially disrupt EWS-FLI1 binding
by comparison to p53 binding to their respective cognate DNA targets in vitro. In cell-based assays, low concentrations of
actinomycin D preferentially blocked EWS-FLI1 binding to chromatin, and disrupted EWS-FLI1-mediated gene expression.
Higher concentrations of actinomycin D globally repressed transcription. These results demonstrate that actinomycin D
preferentially disrupts EWS-FLI1 binding to DNA at selected concentrations. Although the window between this preferential
effect and global suppression is too narrow to exploit in a therapeutic manner, these results suggest that base-preferences
may be exploited to find DNA-binding compounds that preferentially disrupt subclasses of transcription factors.
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Introduction
Ewing sarcoma predominantly affects adolescent and young
adults, representing almost 3% of pediatric cancers [1,2]. While
the overall cure for patients with non-metastatic disease is
approximately 70%, patients with metastatic disease have less
than 20% 5-year event-free survival [3]. Accordingly, there is a
significant unmet need for improved therapies to treat Ewing
sarcoma.
A majority of Ewing sarcomas contain a translocation that fuses
the EWS gene on chromosome 22 to the FLI1 gene on
chromosome 11. The chimeric EWS-FLI1 oncoprotein alters the
regulation of wild type FLI1 transcriptional targets [4,5]. In a
minority of cases, the EWS gene is fused to other ETS-family
transcriptional factors such as ERG and ETV1 [6,7]. Previous
studies have shown that depletion of EWS-FLI1 results in cell cycle
arrest and apoptosis in Ewing sarcoma cells [8,9,10], indicating
that EWS-FLI1 may be an attractive therapeutic target [11,12].
Unfortunately, conventional drug discovery approaches have not
been as successful in targeting transcriptional factors by compar-
ison to other target classes such as kinases and receptors.
One way to attenuate transcription factor activity is to block
binding to the cognate DNA targets. For example, polyamide-
based compounds have been shown to be able to bind DNA in a
sequence-preferential manner, and to block the binding of
transcription factors such as NF-kB [13] and hypoxia-inducible
factor [14]. Prior focused and genome-wide analyses have shown
that EWS-FLI and FLI1 bind to distinct regions of the genome,
and have identified a consensus cognate binding motif for EWS-
FLI1 [15,16,17]. Using this knowledge, we designed a high-
throughput screening (HTS) assay to identify compounds that
block the binding of recombinant EWS-FLI1 to a cognate
oligonucleotide target. We used this HTS assay to screen libraries
enriched for bioactive molecules, demonstrating that a variety of
DNA-binding agents disrupt binding of EWS-FLI1 to DNA.
Although no EWS-FLI1-specific inhibitors were found, some
compounds, such as actinomycin D, did demonstrate preferential
disruption of EWS-FLI1 binding.
Materials and Methods
Cell lines and Materials
All Ewing sarcoma cell lines were obtained from American
Type Culture Collection (ATCC) and cultured in DMEM with
10% FCS or RPMI-1640 with 15% FCS (Life Technologies).
Rearrangement of the EWS locus was verified in all Ewing
sarcoma cell lines by split probe fluorescence in situ hybridization
(FISH) at Genzyme. CellTiter 96 non-radioactive cell proliferation
assay (MTT) was purchased from Promega. Absolutely RNA
microprep kit was obtained from Stratagene. SuperScript III
one-step RT-PCR system with platinum Taq high fidelity, BL21
(DE3) and DH5 alpha competent cells were purchased from Life
Technology. X-tremeGene HP transfection reagent was obtained
from Roche. BugBuster Protein Extraction Reagent was obtained
from Novagen. AlphaScreen streptavidin conjugated donor beads
and glutathione conjugated acceptor beads were obtained from
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PerkinElmer. All oligos were synthesized by Integrated DNA
Technologies. Normal rabbit IgG was purchased from Cell
Signaling Technology. ChIP-IT Express Chromatin Immunopre-
cipitation Kits were purchased from Active Motif. iScript One-
Step RT-PCR Kit for Probes and iQ SYBR Green Supermix were
obtained from Bio-Rad. Chemicals were purchased from Sigma-
Aldrich and EMD Chemicals. Miniprep and Maxiprep DNA
purification kits, PCR purification kits, DNA Gel extraction kits
were obtained from Qiagen. All restriction enzymes, calf intestinal
alkaline phosphatase (CIP) and T4 DNA ligase are purchased
from New England Biolabs. p53-GST fusion protein expression
plasmid was a kind gift from Dr. Guangchao Sui of Wake Forest
University. 10X Tris Buffered Saline (TBS) was purchased from
Boston BioProducts.
AlphaScreen Assay
An AlphaScreen assay for binding of recombinant EWS-FLI1 to
DNA was previously described [18]. Briefly, recombinant EWS-
FLI1 and p53 were synthesized in bacteria transformed with
pGex-6P-1-EWS-FLI1 or pGex-6P-1-p53, and bound to AlphaSc-
reen acceptor beads. A biotinylated oligonucleotide containing two
copies of the EWS-FLI1 binding motif or p53 binding motifs was
bound to AlphaScreen donor beads. For EWS-FLI1, the oligo
sequence was: ATGACACTGACCCGCCTACTACCG-
GAAGCGACCGGAAGCGCCCATCGCTC. The p53 binding
oligo sequence was: GTCCAGTTAGTCTCCGA-
TAACGCTGCCTAAGGTCACGAATTGACATAGC-
CAATGCGCTGT. This assay was used to screen 5,200
compounds, as previously described [18]. IC50 values were
calculated with the GraphPad Prism software package.
Figure 1. Biochemical disruption of EWS-FLI1 and p53 binding to DNA. Dose response for disruption of recombinant EWS-FLI1 (red lines)
and p53 (black lines) binding to DNA in the presence of indicated compounds was measured using AlphaScreen proximity assays. Data plotted as
mean +/2 SD of triplicate samples and are representative of 2 independent experiments.
doi:10.1371/journal.pone.0069714.g001
Table 1. AlphaScreen Results.
IC50 (nM)
Compound EWS-FLI1 p53
Actinomycin D 45 .10000
Aminopurvalanol A 1833 1202
Amiodarone HCl 5362 5288
Cisplatin 5391 8866
Clofazimine 202 203
DMBI 3371 3780
Daunorubicin 4482 8804
Doxorubincin 344 1216
Ebselen 631 .10000
Epirubicin 42 389
Erk inihibitor 3352 .10000
Ethoxyqiun 464 484
Go 6976 .10000 2813
Omeprazole 7328 26721
Phenylmericuric Acetate 16 25
Quinacrine HCl 7033 6055
Reversine 2416 2709
Shikonin 600 633
Verteporfin 342 86
doi:10.1371/journal.pone.0069714.t001
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Luciferase Reporter Assays
The NR0B1 promoter was amplified from human genomic
DNA using the 59 primer- aaagctagcttcctcttatgctgagaattc and 39
primer - gccaagcttggcgcccgtagcccagttctg. NR0B1 promoter am-
plicon was cloned into the NheI and HindIII sites in the
pGL.3Basic vector. The 59 primer-aaagctagctgcaagtgggagctaaa-
taaag was used to amplify a truncated NR0B1 promoter in which
the entire EWS-FLI1 binding region (GGAA repeats) was deleted
to construct pGL.3b-NR0B1del. All constructs were confirmed by
sequencing. All other plasmids were previously described [18].
Cells were grown in 6 well plates to approximately 50%
confluence. A total 3.06 mg of DNA (0.9 mg of pGL.3b-NR0B1 or
pGL.3b-NR0B1del, 0.06 mg of pGL.3b-UbC-RL and 2.1 mg of
pCMV-tag4a-EWS-FLI1 or pCMV-tag4a empty plasmid) was
mixed with 291 ml of serum free Opti-MEM medium. The
mixtures were kept at room temperature for five minutes, then
9 ml of X-tremeGene HP was added. DNA and X-tremeGene HP
mixtures were kept at room temperature for fifteen minutes, then
100 ml of the mixture was added to each well of a 6-well plate.
Twenty four hours post-transfection, cells were lysed in 200 ml of
lysis buffer and 10 ml of cell lysate was used for the dual luciferase
assay.
Ewing sarcoma A673 cells at 50% confluence in 100 mm dishes
were transfected with both 5.8 mg of pGL.3b-NR0B1 and 0.2 mg
of pGL.3b-Ubc-RL reporter plasmids as above. Eight hours post-
transfection, cells were trypsinized and 600 ul (26105) of cells were
added to each well of 24 well plates. 5 ml of different concentration
of compounds or DMSO control were added to each well. Each
treatment was performed in triplicate. Cells were incubated for 16
hours, then cells were lysed in 100 ml of lysis buffer and 10 ml of
cell lysate was used for the dual luciferase assay. Renilla luciferase
activity was used as an internal control for normalization of
nonspecific transcriptional inhibition or cytotoxic effects. Exper-
iments were repeated three times. IC50 values were calculated
using Prism (Graphpad).
Chromatin Immunoprecipitation Assay
ChIP-qPCR was performed as previously described [18].
Briefly, cells were treated with compounds for 4 hrs, then
crosslinked, lysed, and chromatin fragmented. After ChIP,
quantitative PCR was used to quantify NR0B1, p53, and RPS26
loci, and fold enrichment was determined by the formula: Fold
enrichment = 2ˆ(Input Ct-ChIP Ct)/2ˆ(Input Ct-IgG Ct).
Quantitative RT-PCR
Duplicate wells of A673 cells were treated overnight with
different concentration of actinomycin D. RNA was extracted with
absolutely mRNA purification kit from Stratagene. 0.5 mg total
RNA was mixed with 1 ml iScript Reverse Transcriptase, 10 ml of
26 RT-PCR reaction mix for probes from Bio-Rad, 1 ml of
NR0B1, RPS26 and TP53 probes from Life Technologies and
H2O up to 20 ml total volume. RT-PCR was performed in an
iCycler iQ with 50uC for 10 minutes for one cycle; 95uC, 15
seconds, 60uC 40 seconds for 40 cycles. Each RNA sample was
technically duplicated, and relative abundance was calculated by
the delta Ct method.
Figure 2. Effect of actinomycin D on gene expression. Effects of actinomycin D (A), epirubicin (B) doxorubicin (C), ebselen (D) and Erk inhibitor
(E) on NR0B1-Luc (solid line) and UbC-Renilla (dotted line) reporter activity. Data plotted as mean +/2 SEM of triplicates. F: Quantitative RT-PCR was
used to determine the abundance of NR0B1, TP53 and RPS26 mRNA after overnight treatment of A673 cells with the indicated concentrations of
actinomycin D. Results normalized to DMSO control. Data plotted as mean +/2 SD of quadruplicates, and are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0069714.g002
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Cell Viability
Cells were seeded at a density of 1.56105/ml with 100 ml/well
in 96 well plates and treated with actinomycin D at 158 nM,
50 nM, 15.8 nM, 5 nM, 1.58 nM, 0.5 nM and 0 (6 wells/
treatment) for 44 hours. CellTiter 96 was used to assess cell
viability after a 2 hr incubation at 37uC. IC50 values were
calculated using Prism.
Lentivirus Production and Viral Transduction
Lentiviral plasmids targeting FLI1- (clone ID
TRCN0000005322, target sequence CGTCATGTTCTGGTTT-
GAGAT) and LacZ (clone ID TRCN0000072223, target
sequence TGTTCGCATTATCCGAACCAT) were obtained
from the RNAi Consortium and packaged according to the RNAi
Consortium protocols. When A673 cells were 30 to 35% confluent
in 100 mm dishes, growth media was removed and 5 ml fresh
media added along with 5 ml of virus and Polybrene at a final
concentration of 8 mg/ml. After 24 hours, media was replaced
with 10 ml fresh growth media containing puromycin at 4 mg/ml.
Cells were selected for 48 hours, then harvested for Western-blot
and RNA extraction.
Gene Expression Profiling
Ewing sarcoma A673 cells at 65% confluence were treated in
duplicate with DMSO (0.2%) or 5 nM actinomycin D for 24
hours. RNA was extracted with an Absolutely RNA kit. 100 ng of
total RNA was hybridized to Affymetrix Gene 1.0 ST Arrays
(DFCI Microarray Core Facility). Array quality was verified before
background correction, RMA normalization and log2 conversion
using the Bioconductor R package affy (URL: http://www.
bioconductor.org). Differential gene expression was determined
using the limma Bioconductor package. Genes with a fold-change
.2 and Benjamini-Hochberg-corrected [19] p-value ,0.01 were
retained for further consideration. Gene expression data have
been deposited in GEO (GSE45414) and can be accessed at URL:
http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc =GSE45414.
Results
Biochemical Disruption of EWS-FLI1 Binding
We developed a homogeneous AlphaScreen assay to assess the
binding of recombinant EWS-FLI1 to DNA [18]. A parallel assay
assessing binding of p53 to DNA was used as a counterscreen.
Briefly, in these proximity assays, recombinant GST-EWS-FLI1 or
GST-p53 was bound to glutathione-conjugated AlphaScreen
acceptor beads, and a synthetic biotinylated oligonucleotide (oligo)
containing tandem EWS-FLI1 or p53 binding sites was bound to
streptavidin-conjugated AlphaScreen donor beads. Binding of
GST-EWS-FLI1 or GST-p53 to the cognate oligo allows singlet
oxygen transfer from donor to acceptor beads when excited at
680 nm, with resulting light emission between 520–620 nm.
Using these assays, we screened 7 bioactive-enriched small
molecule libraries, totaling 5,200 compounds (ICCB, Harvard
Medical School), with an average Z’-factor of 0.84. A total of 19
compounds were found to disrupt the binding of EWS-FLI1 to its
cognate DNA binding sequence with an IC50,10 mM (Figure 1,
Table 1). Actinomycin D was found to have the greatest
differential effect in the parallel assays, with an IC50 of 46 nM
for EWS-FLI1 binding compared to .10,000 nM for p53
(Figure 1, Table 1). Actinomycin D, a chemotherapeutic agent
isolated from soil bacteria [20], is a well known DNA-binding
agent [21,22,23,24,25,26,27,28]. Epirubicin, a DNA intercalating
anthracycline and Ebselen, a mimic of glutathione peroxidase, also
demonstrated some separation in disruption of EWS-FLI1 binding
(IC50 42 nM and 631 nM respectively) in comparison to p53 (IC50
389 nM and .10,000 nM respectively). By contrast, several other
DNA-binding chemotherapeutic agents were found to disrupt
both EWS-FLI1 and p53 binding similarly (cisplatin, daunorubi-
cin, doxorubicin). These results demonstrate that in a biochemical
assay, there are differences between DNA binding agents in their
ability to disrupt binding of EWS-FLI1 compared to p53.
Inhibition of EWS-FLI1 Activity in Cells
To determine the effect of compounds on EWS-FLI1 activity in
cells, we used a reporter assay comprised of the NR0B1 promoter,
a prototypical EWS-FLI1-regulated gene [15], driving expression
of firefly luciferase. Renilla luciferase driven by the Ubiquitin C
promoter (UbC-RL) was used as an internal control. Confirming
prior studies [15], the NR0B1 promoter was verified to be highly
responsive to EWS-FLI1, whereas the UbC promoter activity was
not subject to regulation by EWS-FLI1 (Figure S1).
We co-transfected A673 Ewing sarcoma cells with NR0B1-Luc
and UbC-RL reporters and treated cells with the compounds that
scored positive in the AlphaScreen assay. For actinomycin D, the
IC50 for inhibition of NR0B1 activity was 2.8 nM, whereas
inhibition of UbC promoter activity was 14 nM (Figure 2A). In
contrast, other compounds such as epirubicin (Figure 2B) and
doxorubicin (Figure 2C) demonstrated no separation for inhibition
of the NR0B1 and UbC reporters. Even though Erk inhibitor and
ebselen demonstrated preferential inhibition of EWS-FLI binding
to its target DNA in vitro (Figure 1, Table 1), both modulated the
NR0B1 and UbC reporters equally in intact cells (Figure D and E).
Thus, actinomycin D was the only compound that demonstrated
preferential disruption of EWS-FLI1 binding in vitro and reporter
activity in cells.
We next examined the effects of actinomycin D on the
endogenous expression of NR0B1. As controls, we examined the
expression of 2 transcripts that are not EWS-FLI1 targets (p53 and
RPS26). Consistent with the reporter assay results (Figure 2A),
expression of endogenous NR0B1 mRNA was preferentially
attenuated at low concentrations of actinomycin D (5 -10 nM,
Figure 2F). At higher concentrations, expression of NR0B1 and
control transcripts were similarly attenuated (50 nM, Figure 2F).
These results suggest that actinomycin D preferentially inhibits
EWS-FLI1 in cells, however the window between this preferential
effect and global inhibition of transcription is narrow (,10-fold).
Global inhibition of EWS-FLI1 Activity
To determine if the effects of actinomycin D on EWS-FLI1
target genes extended beyond NR0B1, we defined a set of EWS-
FLI1 regulated genes by shRNA depletion of EWS-FLI1 in A673
cells. Cells were harvested and divided into two parts for Western-
blot to determine protein levels (Figure S2) and RNA extraction
for gene expression profiling 48 hrs after infection with a FLI1-
targeting shRNA virus or a LacZ-targeting shRNA virus as a
control. Genes whose expression was reduced at least 50% after
knock-down of EWS-FLI1 (Table S1) were collated to form a gene
set of EWS-FLI1 activated genes in A673 cells. A comparison of
this gene signature to gene sets (C2 - curated and pathway gene
sets, C3 - predicted transcription factor targets, and C5 -
functional annotations) available from the Molecular Signatures
Database (MSigDB) revealed strong enrichment for previously
published EWS-FLI1 target gene sets (Figure 3A, limited to gene
sets encompassing at least 10% of our EWS-FLI induced
signature). Enrichment for E2F target genes was likely due to
the anti-proliferative effects of EWS-FLI1 depletion.
Actinomycin D Preferentially Disrupts EWS-FLI1
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We used Gene Set Enrichment Analysis (GSEA) to determine if
treatment with low concentrations of actinomycin D resulted in a
coordinated repression of EWS-FLI1-activated genes, effectively
mimicking suppression by shRNA. The gene set comprised of
EWS-FLI1-induced genes was among the curated signatures most
robustly down-regulated by treatment with 5 nM actinomycin D
(Figure 3B, red diamond). Consistent with the enrichment of E2F
targets among EWS-FLI1-induced genes we noted in the shRNA
study above (Figure 3A), we also found down-regulation of this
class of signatures in A673 cells treated with low-dose actinomycin
D (Figure 3B, black circles). Indeed, EWS-FLI1-induced genes
which are highly expressed in control-treated A673 cells are
repressed to a significant degree by 5 nM actinomycin D
(Figure 3C). These results demonstrate that low concentrations
of actinomycin D not only attenuates expression of NR0B1
(Figure 2D), but generally suppresses EWS-FLI1 mediated gene
expression (Figure 3C).
Disruption of EWS-FLI1 Binding to Chromatin
We used chromatin immunoprecipitation coupled with quan-
titative PCR (ChIP-qPCR) to assess effects of actinomycin D on
EWS-FLI1 binding to chromatin in cells. A673 cells were treated
with either actinomycin D at 5 nM, or vehicle. After crosslinking,
chromatin was sheared and EWS-FLI1-DNA complexes were
immunoprecipitated using an anti-FLI1 antibody. We used
primers flanking the EWS-FLI1-binding site in the promoter of
the NR0B1 gene [15] to quantify binding of EWS-FLI1. We used
RPS26 and TP53 as control loci since neither are bound by EWS-
FLI [15] and we have shown that RPS26 and TP53 transcript
levels were unaffected by actinomycin D treatment (Figure 2F).
Without actinomycin D treatment, binding of EWS-FLI1 to the
NR0B1 promoter was enriched 31-fold by comparison to IgG
controls (Figure 4A, DMSO). Treatment of cells with actinomycin
D reduced binding of EWS-FLI1 to the NR0B1 promoter to 4-fold
(p=0.0018; Figure 4A). Actinomycin D treatment did not affect
either RPS26 or TP53 loci (Figure4 B–C). These data demon-
strates that low concentrations of actinomycin D blocks the
Figure 3. Effects of actinomycin D on EWS-FLI1 target gene expression. A. Genes down-regulated at least 2-fold by shRNA against EWS-FLI
(adjusted p-value,0.01) were used to interrogate curated (C2 pathways, C5 gene ontology) and predicted (C3 transcription factor) gene sets. Shown
are overlapping gene sets that encompassed at least 10% of the 102 EWS-FLI signature genes represented in MSigDB. B. Plot of normalized signature
enrichment score vs FDR from GSEA using transcription factor signatures to distinguish cells treated with 5 nM actinomycin D from control. Subsets
of signatures for E2F and ETS-family members are highlighted for comparison with gene sets induced or repressed by EWS-FLI. C. GSEA plot showing
the down-regulation of EWS-FLI target genes by treatment with 5 nM actinomycin D.
doi:10.1371/journal.pone.0069714.g003
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interaction of EWS-FLI1 with the NR0B1 promoter within intact
cells.
Comparative Sensitivity to Actinomycin D
The studies above suggest that at low concentrations of
actinomycin D, the binding of EWS-FLI1 is preferentially
displaced from DNA. To determine if cells driven by EWS-FLI1
are more sensitive to actinomycin D, we assessed cell growth and
viability using a MTT assay after 44 hrs exposure to actinomycin
D. Although all cell lines were affected by actinomycin D, the
Ewing sarcoma cell lines were as a group more sensitive by
comparison to other cell lines tested (Figure 5). These results are
consistent with the biochemical and cellular finding that low
concentrations of actinomycin D preferentially disrupts EWS-FLI1
in Ewing sarcoma cells.
Discussion
The EWS-FLI11 oncoprotein drives the development of Ewing
sarcoma and is a propitious therapeutic target. In order to identify
compounds that disrupt the binding of EWS-FLI1 to its cognate
target genes, we develop a high throughput biochemical assay and
used it to screen 5,200 small molecule bioactive compounds. Not
surprisingly, we found that a number of DNA-binding agents
disrupted the binding of EWS-FLI1 to DNA, and that most also
disrupted the binding of p53 to DNA, indicating a lack of
specificity. Actinomycin D was the only compound that demon-
strated preferential blockade of EWS-FLI1 binding in biochemical
and cell-based assays. Previous studies using a variety of methods
including NMR [21,25,27,28,29], DNA footprinting [22,23,26],
and X-ray diffraction [24,30] have demonstrated sequence-specific
binding of actinomycin D to dGpC, ATGCAT and T(G)nT where
n varies from 1 to 4 guanine residues [31]. While none of these
known sequence preferences correspond to a cognate EWS-FLI1
binding sequence, these results demonstrate that actinomycin D
binds to different DNA sequences with different affinities,
suggesting a possible explanation for the preferential disruption
of EWS-FLI1 binding. Specifically, low concentrations of actino-
mycin D may occupy the highest affinity sites (e.g., ATGCAT), the
cognate EWS-FLI1 binding sequences may represent moderate
affinity sites, whereas high concentrations of actinomycin D would
occupy low affinity sites resulting in widespread blockade of
transcription factor binding to DNA.
The preferential disruption of EWS-FLI1 binding at low
concentrations of actinomycin D is apparent not only in
biochemical assays, but also in cell-based assays. Using gene
expression profiling, we can demonstrate that the disruption of
EWS-FLI1 mediated gene expression is not limited to the NR0B1
gene, but is widespread across all EWS-FLI1 target genes. We
suspect that this widespread disruption of EWS-FLI1 activity may
be responsible for the heightened sensitivity of Ewing sarcoma cells
to actinomycin D. These results are reminiscent of prior studies
demonstrating that mithramycin and ET-743 (trabectedin), both
DNA binding agents, reduced expression of EWS-FLI1 down-
stream targets and inhibited the growth of Ewing sarcoma cells
[11,12].
Unfortunately, while actinomycin D concentrations can be
precisely titrated in vitro, the use of actinomycin D in vivo is subject
to pharmacokinetics whereby constant drug levels at a precise
concentration are not possible to achieve. Therefore, these in vitro
and cell-based studies are not readily translatable to in vivo utility.
However, together these results demonstrate that DNA-binding
agents do demonstrate differential specificity, likely due to
preferential sequence binding affinities. These results suggest that
compounds with even greater sequence specificity may be
identified either through expanded screening (and counter-
screening), or through medicinal chemical modification of existing
DNA-binding agents (SAR for specific disruption of EWS-FLI1).
Figure 4. Effects of actinomycin D on the binding of EWS-FLI1 to the NR0B1 promoter. EWS-FLI1 was immunoprecipiatated using a FLI1
antibody, and quantitative PCR used to determine binding to NR0B1, RPS26, and p53. Data expressed as fold-enrichment over normal IgG control
ChIP. Data plotted as mean +/2 SD of duplicates are representative of 3 independent experiments.
doi:10.1371/journal.pone.0069714.g004
Figure 5. Growth effects of actinomycin D on Ewing sarcoma
and other cancer cell lines. Cells were treated with DMSO or
actinomycin D for 44 hours. Viable cell number was determined
with a MTT assay. Data plotted as mean +/2 SD of sextuplets and are
representative of 3 independent experiments.
doi:10.1371/journal.pone.0069714.g005
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Compounds would ideally have a wide therapeutic window
between disruption of EWS-FLI1 binding and other transcription
factors (specificity) and pharmacokinetic properties that allow
clinically achievable drug levels within this therapeutic window.
Identification of compounds with such properties may allow in vivo
and clinical translation to specifically target EWS-FLI1 dependent
tumors.
Supporting Information
Figure S1 NR0B1 reporter is driven by EWS-FLI1. A.
HeLa cells were transfected with both NROB1-firefly luciferase
and UbC-renilla reporters, and with or without EWS-FLI1
expression vector. Data plotted as mean +/2 SD of triplicates.
B. HeLa cells were transfected with NROB1-firefly luciferase
reporter and with a graded amount of EWS-FLI1 expression
vector. Data plotted as mean +/2 SD of triplicates. C. Ewing
sarcoma A673 cells were transfected with NR0B1-Luc reporter
with either EWS-FLI1 binding sites deleted (1) or intact (2). Data
plotted as mean +/2 SD of triplicates.
(TIF)
Figure S2 shRNA knock-down of EWS-FLI1. A673 cells
were infected with lentiviruses encoding FLI1-targeting shRNA or
a control LacZ-targeting shRNA for 48 hours. Western blot was
used to assess abundance of EWS-FLI1 compared to beta-actin as
a loading control.
(TIF)
Table S1.
(DOC)
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